IBI-325

• Description :

  IBI-325 is a humanized monoclonal antibody inhibitor targeting CD73. IBI-325 completely inhibits CD73 enzymatic activity without hook effect. IBI-325 reverses Adenosine monophosphate (HY-A0181) -mediated immune suppression and significantly inhibits T cell proliferation and cytokines (IL-2, IFN-γ and TNF-α) release. IBI-325 has potent antitumor activities in hPBMC-reconstituted mice model and hCD73 knock-in mice model. IBI-325 can be used for cancer immunotherapy research[1].

• UNSPSC :

  12352100

• Target :

  CD73; IFNAR; Interleukin Related; TNF Receptor

• Related Pathways :

  Apoptosis; Immunology/Inflammation

• Field of Research :

  Cancer; Inflammation/Immunology

• References & Citations :

  [1]Zhou Y, et al. Pharmacology, pharmacokinetics, and toxicity characterization of a novel anti-CD73 therapeutic antibody IBI325 for cancer immunotherapy. Int J Biol Macromol. 2023 Feb 28;229:158-167.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  No Development Reported

• Isoform :

  IL-2